preeclampsia
Conditions
Interventions
Oral low-dose aspirin group in high-risk population of preeclampsia:NA
Sponsors
Chengdu Third People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. >= 18 years old; 2. Single pregnant women with a high risk group preventive use of aspirin to prevent preeclampsia (high risk factor 3 points/item, medium risk 2 points/item, low risk 1 point/item, total score >= 3 points) are high-risk groups. Risk factor classification: high risk factors: history of preeclampsia, chronic high blood pressure, pregnancy with medical diseases (such as systemic lupus erythematosus, antiphospholipid syndrome, kidney disease, diabetes, etc.), obesity (BMI >= 28.0kg/m ²), pregnant women age >= 40 years old. Medium risk factors: overweight (BMI 24.0~27.9kg/m ²), multiple pregnancies, maternal age 35~10 years, assisted reproductive technology pregnancy, history of gestational hypertension, etc; 3. Can take low-dose aspirin (100 mg/day) orally according to the doctor's advice, and is expected to continue taking the medication until 36 weeks of pregnancy or delivery as directed by the doctor
Exclusion criteria
Exclusion criteria: 1. Contraindications for aspirin: Known allergies to aspirin or other nonsteroidal anti-inflammatory drugs. History of active gastrointestinal ulcers or bleeding. Suffering from asthma, hemophilia, or other hemorrhagic diseases. 2. Combined severe diseases: Combined severe liver and kidney dysfunction (defined as baseline indicators exceeding 1.5 times the upper limit of normal values). Merge uncontrolled hyperthyroidism or hypothyroidism. Combining malignant tumors, severe cardiovascular diseases, neurological disorders, or mental illnesses, unable to cooperate with research. 3. Pregnancy related situation: This pregnancy is a multiple pregnancy conceived through assisted reproductive technology (due to its more complex pharmacokinetics, it can be studied independently). Discovery of significant structural abnormalities or chromosomal abnormalities in the fetus. 4. Combination therapy interference: Long term use of drugs that may interfere with the pharmacokinetics or efficacy of aspirin is required during the study period, such as other anticoagulant/antiplatelet drugs such as low molecular weight heparin, clopidogrel, etc. High dose glucocorticoids. Other nonsteroidal anti-inflammatory drugs (such as ibuprofen, naproxen). 5. Other factors: Researchers determine the presence of any other factors that may interfere with the evaluation of research results or place pregnant women in high-risk situations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aspirin concentrations; | — |
Secondary
| Measure | Time frame |
|---|---|
| sFlt-1; | — |
Countries
China
Contacts
Public ContactYang Ou
Chengdu Third People's Hospital
Outcome results
None listed